A new generation of nano-medicines for the treatment of HIV/AIDS, Hepatitis-C and other viral infections is being developed by Vecoy Nanomedicines Ltd., a privately held company based out of the Bar-Ilan Institute of Nanotechnology and Advanced Materials (BINA).
Dr. Ido Bachelet
The technology uses nan-scale virus traps that mimic human cells, and by doing so lure and destroy virus particles. This revolutionary anti-viral approach (patent pending) has the potential to become a life-saving medical breakthrough.
The company, which won first prize in Israel’s “Start-Up of the Year” competition, is currently collaborating with Dr. Ido Bachelet, a DNA-nanotech expert, who came to BIU from Harvard University. Dr. Bachelet leads a multidisciplinary group developing and studying emerging biologically-inspired technologies.
In addition, the company collaborates with BIU Prof. Shlomo Margel, an authority on nanoparticles, and hopes in the future to expand cooperation to include additional BIU labs.
“It is a privilege working with BINA scientists,” says Vecoy CEO Erez Livneh. “BIU has cutting-edge nanotechnology capabilities and state-of-the-art microscopy.”
To learn more about Dr. Bachelet’s nanobots research that is changing medicine, view his videotaped lecture:
